Arthneeti

Indraprastha Medical Corporation Share Price & Earnings Call Analysis

₹318.40+2.49% today
Market cap
₹2,919 Cr
P/E
15.19
ROE
27.35%
PEG
0.54
Price to sales
1.88
Debt to equity
0.04
52W high / low
₹623 / ₹300
Sales growth (5Y)
19.30%
EBITDA margin
17.98%
Net profit margin
12.33%
Promoter holding
51.00%
Sales (last year)
₹1,555 Cr

Potential multibaggers · Q2 FY27

Potential multibaggers in Healthcare Services
on management's own guidance

  1. Strong growth
    2
  2. Strong growth
    1
  3. Aster DM Quality Care LtdGood growth
    3
See all potential multibaggersWhere does Indraprastha Medical Corporation rank?

Portfolio builder

Build your portfolio
from the top-ranked stocks

  1. 1. Pick 3–15 stocks
  2. 2. Choose large, mid or small cap and your sectors
  3. 3. Get a portfolio built from the rankings
Build my portfolio

Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.

Peers

Healthcare Services companies ranked on guidance

#CompanyRevenue guidedMargin guidedMarket capP/E
140%+Up 2%+₹921 Cr—
240%+Flat₹575 Cr21.9
3Aster DM Quality Care Ltd20–40%Up 2%+₹59,405 Cr164.6
420–40%Up 2%+₹551 Cr18.5
520–40%Up 0–2%₹1,635 Cr16.5
620–40%Flat₹1.21L Cr57.7

Sign up free to see every company in the sector ranking and track Indraprastha Medical Corporation.

Pro shows every company guiding 40%+ revenue growth →Full Healthcare Services ranking

Financials of Indraprastha Medical Corporation

Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.

Shareholder Pattern

Indraprastha Medical Corporation

Shareholding breakup across reporting periods.

Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Promoters +51.00%51.00%51.00%51.00%51.00%51.00%51.00%51.00%51.00%51.00%51.00%51.00%
FIIs +0.95%1.08%1.70%2.64%2.88%2.94%2.73%2.41%2.72%2.43%2.77%2.39%
DIIs +6.36%4.91%3.14%3.19%3.18%3.56%3.56%3.51%0.82%0.87%0.59%1.77%
Public +41.69%43.01%44.14%43.16%42.91%42.50%42.74%43.08%45.43%45.69%45.65%44.83%
No. of Shareholders51,44854,15855,10364,67169,69770,49170,21170,91471,22572,98075,09877,706

Financials of Indraprastha Medical Corporation

Quarterly Results

Quarter-by-quarter operating performance

Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Sales +317306315348350325334365381372365406413
Expenses +267259266281286273272292310310304326335
Operating Profit50474867645261737162618077
OPM %16%15%15%19%18%16%18%20%19%17%17%20%19%
Other Income +4455656777789
Interest1122221221122
Depreciation10101011111111101111111212
Profit before tax44414260574555686656557572
Tax %25%28%25%25%26%26%26%25%25%27%24%25%26%
Net Profit +33293145423341514941425654
EPS in Rs3.583.213.404.884.633.584.475.615.404.474.556.095.84

Financials of Indraprastha Medical Corporation

Profit & Loss

Annual income statement trend

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales +7147557667537888316138881,0991,2451,3561,4831,555
Expenses +6306756866787067435727689471,0501,1121,2151,276
Operating Profit85807974828741120152195245267280
OPM %12%11%10%10%10%11%7%14%14%16%18%18%18%
Other Income +11-0-1-1-0-0-3916222831
Interest8789763344666
Depreciation28353131303333353940444447
Profit before tax503941344548479117166216246258
Tax %34%37%36%38%36%9%46%26%26%25%26%25%
Net Profit +32242621284425986124161184192
EPS in Rs3.542.662.862.303.104.760.256.399.4013.5217.5620.0320.95
Dividend Payout %51%68%63%65%52%0%0%39%32%33%26%20%

Financials of Indraprastha Medical Corporation

Balance Sheet

Capital structure and asset base

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Sep 2026
Equity Capital92929292929292929292929292
Reserves103132139141152176181234288386505649723
Borrowings +5052676621435234333735
Other Liabilities +196185160134157177157131173212222214269
Total Liabilities4424604584324224494324625557238529911,118
Fixed Assets +286301296294280303283277275347328365387
CWIP33001030303333
Investments000000000000142
Other Assets +153157163138141146145185278376491624586
Total Assets4424604584324224494324625557238529911,118

Financials of Indraprastha Medical Corporation

Cash Flows

Operating, investing and financing cash movement

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity +6462284875862794144200157167
Cash from Investing Activity +-29-33-22-30-17-40-19-74-108-158-111-178
Cash from Financing Activity +-35-30-5-17-44-43-3-3-26-32-46-46
Net Cash Flow-0-0-01144517119-0-57
Free Cash Flow35295175846665100131120108
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit98%104%57%82%110%113%88%95%102%127%89%88%

Financials of Indraprastha Medical Corporation

Ratios

Working capital efficiency and return ratios

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days404147413535401823172028
Inventory Days
Days Payable
Cash Conversion Cycle404147413535401823172028
Working Capital Days-35-22-17-7-5-10-1-2-12-24-19-4
ROCE %23%18%17%15%19%21%3%29%34%38%39%36%
7out of 100

Momentum score · price trend

7 out of 100 — Cooling

Over the past year its share price has done worse than most of the stocks we track.

PeriodShare price changeBetter than … of 1,910 stocks
Last 12 months−48.8%5%
Last 6 months−24.8%13%
Last 3 months−15.8%30%

The price is 50.1% below its all-time high of ₹622.8 (6 Nov 2025). Stocks more than 20% below their peak have their score halved, so 13 became 7.

How we calculate it

“Better than 30%” means that over that period the share price did better than 30 out of every 100 stocks we track (1,910 Indian companies worth ₹500 Cr or more, with at least a year of prices).

The score weighs the longer periods more: 40% × 12-month + 40% × 6-month + 20% × 3-month. For Indraprastha Medical Corporation: 0.4 × 5 + 0.4 × 13 + 0.2 × 30 = 13, halved to 7 because the price is more than 20% below its all-time high.

Strengthening is 70 and above, Steady 40 to 70, Cooling below 40. Scores are recalculated every night after the market closes.

Full methodology →

This describes only how the share price has moved up to 2 Nov 2026, compared with other stocks. It says nothing about the business, and it is not a prediction, a price target or a recommendation to buy or sell.

Continue your research

Others in Healthcare Services this season

  • Vijaya Diagnostic Centre (Q2 FY27)

    Q2 FY27 Revenue from Operations: INR 2,554 Mn, up 26.7% YoY (Page 10, 9) . Key investor presentation takeaways from Vijaya Diagnostic Centre Ltd's Q2 FY27 inves

  • Shalby (Q2 FY27)

    Consolidated Total Revenue for Q2 FY27: ₹3,182 million vs ₹2,899 million in Q2 FY26, up 9.8% YoY (Pages 5, 6, 8, 9) . Key investor presentation takeaways from S

  • Metropolis Healt (Q2 FY27)

    Q2FY27 revenue from operations: INR 496.8 Cr, up 15.8% YoY (Page 11) . Key investor presentation takeaways from Metropolis Healthcare Ltd's Q2 FY27 investor pre

  • Nephrocare Health Services (Q2 FY27)

    Q2 FY27 Revenue from Operations: ₹303.4 Cr, up 23.5% YoY from ₹245.7 Cr in Q2 FY26 (Page 9). Key investor presentation takeaways from Nephrocare Health Services

Compare:vs Apollo Hospitalsvs Max Healthcarevs Manipal Health